Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Immediate Lymphatic Reconstruction (ILR)/, Prophylactic Lymphovenous Bypass (pLVB).
- Who it may be relevant to
- Registry conditions: Lymphedema. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial
Overview
To learn if reconstruction of the lymphatic system at the time of axillary lymphadenectomy can reduce the risk of developing lymphedema.
Detailed description
Primary Objectives
\- To determine the freedom from lymphedema (FFL) rate at 2 years postoperatively in participants with a diagnosis of IBC undergoing ILR at the time of ALND.
Secondary Objectives
* Estimate the proportion of participants who have lymphedema that persists at 2 years after ILR surgeries. * Determine baseline lymphatic vessel anatomical or functional characteristics associated with increased risk of lymphedema following ILR. * Evaluate changes in systemic inflammatory mediators and systemic immune cell function affiliated with lymphedema development.
Interventions
- Procedure Immediate Lymphatic Reconstruction (ILR)/
Given by Procedure - Procedure Prophylactic Lymphovenous Bypass (pLVB)
Given by Procedure
Primary outcome measures
- Freedom from lymphedema (FFL) [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Participants diagnosed with IBC.
- Participants who have been scheduled for ILR/pLVB by their treating physician/surgeon at the time of their axillary lymphadenectomy for breast cancer
- Participants willing and able to comply with the study protocol requirements and all study-related visit requirements.
- Female subjects at least 18 years old and capable of providing consent to participate.
- Females of childbearing potential must have a negative urine pregnancy test within 36 hours prior to study drug administration and agree to use a medically accepted method of contraception for a period of one month following the study.
Exclusion criteria
- Patients known to be pregnant or breast-feeding.
- Patients with known or suspected iodine or ICG hypersensitivity.
- Patients unable to remain stationary for one hour.
- Active cellulitis.
- Subjects with a preoperative clinical lymphedema diagnosis.
- Subjects undergoing bilateral ALND.
- Subjects requiring immediate chest wall reconstruction with a pedicled or microvascular flap, or those that have received preoperative radiation therapy.
- Patients with BMI >45kg/m2.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
United States · 1 center
- MD Anderson Cancer Center — Houston
Identifiers
NCT: NCT06989099 · 2024-0255 · NCI-2024-05054